{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
  "id": "02975666",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
  "summary": "### Summary of Material Information:  \n\n- **FY26 Guidance**: Confirmed operating profit forecast of **$20.0\u2013$24.0 million**.  \n- **FY27 Target**: Revenue goal of **$300 million**, with progress on track.  \n- **R&D Pipeline**: Targeting **$8+ billion addressable markets**; includes 8 patented products, 24 off-patent injectables, and an improved migraine treatment.  \n- **Commercialization Programs**: Five advanced R&D projects entering global markets:  \n  - Multiple Maxigesic\u00ae dose forms  \n  - Crystaderm\u00ae (anti-bacterial)  \n  - Micolette\u00ae (bowel obstruction)  \n  - Kiwisoothe\u00ae (tablets/sachets)  \n  - Capsaicin cream (osteoarthritis/neuropathic pain).  \n\n*(No material capital markets or trading actions announced.)*",
  "usage": {
    "prompt_tokens": 1072,
    "completion_tokens": 184,
    "total_tokens": 1256,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:53:11.101946"
}